Financials data is unavailable for this security.
View more
Year on year Lonza Group AG had net income fall -46.17% from 1.22bn to 654.00m despite a 7.94% increase in revenues from 6.22bn to 6.72bn. An increase in the cost of goods sold as a percentage of sales from 60.82% to 64.18% was a component in the falling net income despite rising revenues.
| Gross margin | 29.21% |
|---|---|
| Net profit margin | 8.57% |
| Operating margin | 13.05% |
| Return on assets | 3.23% |
|---|---|
| Return on equity | 5.83% |
| Return on investment | 3.81% |
More ▼
Cash flow in CHFView more
In 2023, Lonza Group AG increased its cash reserves by 9.63%, or 129.00m. The company earned 1.39bn from its operations for a Cash Flow Margin of 20.66%. In addition the company used 1.10bn on investing activities and also paid 152.00m in financing cash flows.
| Cash flow per share | 15.73 |
|---|---|
| Price/Cash flow per share | 35.11 |
| Book value per share | 133.83 |
|---|---|
| Tangible book value per share | 64.37 |
More ▼
Balance sheet in CHFView more
| Current ratio | 2.04 |
|---|---|
| Quick ratio | 1.38 |
| Total debt/total equity | 0.4058 |
|---|---|
| Total debt/total capital | 0.2873 |
More ▼
Growth rates in CHF
Year on year, growth in dividends per share increased 14.29% while earnings per share excluding extraordinary items fell by -45.68%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.65% |
|---|---|
| Div growth rate (5 year) | 7.78% |
| Payout ratio (TTM) | 50.34% |
| EPS growth(5 years) | 0.2499 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -47.86 |
More ▼
